Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Gefitinib in patients with advanced non-small-cell lung cancer].

Pneumonologia i alergologia polska - 1 Jan 2012

Knetki-Wróblewska Magdalena, Kowalski Dariusz M, Zajda Katarzyna, Płużański Adam, Badurak Paweł, Janowicz-Żebrowska Anna, Jaśkiewicz Piotr, Krzakowski Maciej

Abstract excerpt

INTRODUCTION: Patients with advanced non-small cell lung cancer (NSCLC) have a very poor prognosis. Individualization of treatment and identification of therapeutic molecular targets may improve outcomes. Gefitinib was introduced recently among several other molecular-targeted drugs of activity in NSCLC. Gefitinib is indicated for patients diagnosed with advanced or disseminated NSCLC with an activating mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to ErbB Receptors

Share to Gefitinib

Share to Neoplasm Staging

Share to Poland

Share to Quinazolines

Source

Identifiers

PMID: 22926905

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Gefitinib in patients with advanced non-small-cell lung cancer].PMID 22926905Read ↗

Gefitinib for non-small-cell lung cancer treatment.Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.Semantic proximity Read ↗

Gefitinib for advanced non-small cell lung cancer.Semantic proximity Read ↗

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.Semantic proximity Read ↗

Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).Semantic proximity Read ↗

Safety of gefitinib in non-small cell lung cancer treatment.Semantic proximity Read ↗

Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.Semantic proximity Read ↗

[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].Semantic proximity Read ↗

Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.Semantic proximity Read ↗

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.Semantic proximity Read ↗

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.